Brokerages Set LivaNova PLC (NASDAQ:LIVN) PT at $61.17

LivaNova PLC (NASDAQ:LIVN - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the eight research firms that are presently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $61.17.

LIVN has been the topic of several recent research reports. The Goldman Sachs Group lowered their price objective on LivaNova from $64.00 to $55.00 and set a "buy" rating on the stock in a research report on Monday, March 3rd. Mizuho dropped their price target on shares of LivaNova from $70.00 to $60.00 and set an "outperform" rating on the stock in a research report on Wednesday, February 26th. StockNews.com upgraded shares of LivaNova from a "buy" rating to a "strong-buy" rating in a research report on Tuesday, March 25th. Barclays dropped their target price on LivaNova from $58.00 to $56.00 and set an "equal weight" rating on the stock in a research report on Friday, March 7th. Finally, Needham & Company LLC restated a "buy" rating and issued a $64.00 price target on shares of LivaNova in a research note on Monday, March 17th.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of LIVN. Freestone Grove Partners LP purchased a new stake in LivaNova during the 4th quarter worth approximately $23,102,000. Artisan Partners Limited Partnership acquired a new stake in shares of LivaNova in the fourth quarter worth approximately $21,340,000. The Manufacturers Life Insurance Company increased its position in shares of LivaNova by 163.6% during the fourth quarter. The Manufacturers Life Insurance Company now owns 546,387 shares of the company's stock worth $25,303,000 after purchasing an additional 339,139 shares in the last quarter. AQR Capital Management LLC raised its stake in LivaNova by 79.3% in the 4th quarter. AQR Capital Management LLC now owns 742,180 shares of the company's stock valued at $34,214,000 after purchasing an additional 328,313 shares during the last quarter. Finally, Vanguard Group Inc. lifted its holdings in LivaNova by 12.7% in the 4th quarter. Vanguard Group Inc. now owns 2,349,887 shares of the company's stock valued at $108,823,000 after purchasing an additional 265,291 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

LivaNova Stock Performance

Shares of LIVN traded down $0.18 during mid-day trading on Monday, reaching $33.96. The company had a trading volume of 942,766 shares, compared to its average volume of 625,707. The stock has a market capitalization of $1.85 billion, a P/E ratio of 80.86 and a beta of 0.90. LivaNova has a 52-week low of $32.48 and a 52-week high of $64.48. The stock has a 50 day moving average of $41.37 and a two-hundred day moving average of $47.32. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.